Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2013
06/20/2013WO2013089721A1 Thymol and totarol antibacterial composition
06/20/2013WO2013089654A1 Effervescent formulations comprising genistein
06/20/2013WO2013089636A1 Processes for manufacturing of a kinase inhibitor
06/20/2013WO2013089573A1 Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
06/20/2013WO2013089565A1 Improvements in oral health, products and methods therefor
06/20/2013WO2013089533A1 Composition containing tangeretin for external application to the skin
06/20/2013WO2013089479A1 Solid dispersion containing celecoxib, and method for preparing same
06/20/2013WO2013089461A1 Massage patch having fine protrusions and comprising fibers, and method for manufacturing same
06/20/2013WO2013089402A1 Composition comprising gypenoside extract of gynostemma pentaphyllum (thunb.) makino for treating or preventing type ιι diabetes, obesity, or hyperlipidemia
06/20/2013WO2013089383A1 Compound effective for preventing or treating irritable bowel syndrome, and composition containing same
06/20/2013WO2013089346A1 Composition for preventing or treating obesity, dyslipidemia, fatty liver or diabetes containing poly-γ-glutamic acid and isoflavone as active ingredients
06/20/2013WO2013089307A1 Composition for inhibiting after-cataract and method for preparing same
06/20/2013WO2013089283A1 Chimeric double-stranded nucleic acid
06/20/2013WO2013089212A1 Substituted triazine derivative and pharmaceutical composition containing same
06/20/2013WO2013089168A1 Method for producing neuraminic acid derivative
06/20/2013WO2013089164A1 Thromboembolism preventive/therapeutic agent for thromboembolism patients having severe renal dysfunction
06/20/2013WO2013089157A1 Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient
06/20/2013WO2013089140A1 Method for producing antimicrobial composition
06/20/2013WO2013088853A1 Oligonucleotide, glucocorticoid sensitivity enhancer, drug composition, and expression vector
06/20/2013WO2013088449A1 Stable crystal form of febuxostat and process for the preparation thereof
06/20/2013WO2013088446A1 Compositions and methods for modifying a predetermined target nucleic acid sequence
06/20/2013WO2013088445A1 Pyrimidine derivatives for treatment of inflammatory diseases
06/20/2013WO2013088410A1 Antineuritic pharmaceutical combination and compositions
06/20/2013WO2013088404A1 Use of inhibitors of the activity or function of PI3K
06/20/2013WO2013088400A1 Antiangiogenic brassinosteroid compounds
06/20/2013WO2013088389A1 Linezolid premix
06/20/2013WO2013088381A1 Gel compositions
06/20/2013WO2013088380A1 Gel compositions
06/20/2013WO2013088379A1 A topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture
06/20/2013WO2013088376A1 Gel compositions
06/20/2013WO2013088375A1 A topical composition comprising an ingenol derivative and an oily solvent
06/20/2013WO2013088373A1 Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
06/20/2013WO2013088338A1 Micrornas and uses therof
06/20/2013WO2013088335A1 Crystalline form of cabazitaxel and process for preparing the same
06/20/2013WO2013088315A1 Sulfonamide derivatives
06/20/2013WO2013088274A1 Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
06/20/2013WO2013088272A1 Pharmaceutical composition comprising esomeprazole magnesium dihydrate
06/20/2013WO2013088271A1 Modified release liquid pharmaceutical composition comprising bromopheniramine, pseudoephedrine and dextromethorphan
06/20/2013WO2013088257A1 Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors
06/20/2013WO2013088256A1 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (trk) inhibitors
06/20/2013WO2013088254A1 Transdermal delivery system comprising buprenorphine
06/20/2013WO2013088243A1 Compositions of buprenorphine and mu-opioid receptor antagonists
06/20/2013WO2013088242A1 Samidorphan (alks 33) in combination with opioid agonists
06/20/2013WO2013088230A1 Composition for electronic cigarettes
06/20/2013WO2013088191A1 Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
06/20/2013WO2013088162A1 Antimicrobial compounds and methods
06/20/2013WO2013088161A1 Sublingual administration of statins
06/20/2013WO2013088109A1 Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
06/20/2013WO2013088084A1 Phytoecdysones for use in improving the muscle quality of obese and/or sarcopenic mammals
06/20/2013WO2013087965A1 Scorpion‑tail-like macrocyclic compounds and use thereof as antiparasitic agents
06/20/2013WO2013087964A1 Use of agents that alter the peritumoral environment for the treatment of cancer
06/20/2013WO2013087954A1 Compounds that inhibit beta amyloid peptide aggregation
06/20/2013WO2013087943A1 P2x7 antagonists as frontline or adjunctive treatment against status epilepticus
06/20/2013WO2013087936A1 Combination of a prostaglandin receptor agonist and an mc1r receptor agonist for the treatment and/or prevention of pigmentation disorders
06/20/2013WO2013087918A1 Cohesive thin liquids to promote safe swallowing in dysphagic patients
06/20/2013WO2013087815A1 Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
06/20/2013WO2013087808A1 Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
06/20/2013WO2013087807A1 4-aryl imidazole derivatives as mglu5 positive allesteric modiulators
06/20/2013WO2013087806A1 Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors
06/20/2013WO2013087805A1 Piperazine derivatives and their use as positive allosteric modulators of mglu5 receptors
06/20/2013WO2013087794A1 Polymorph of rilpivirine hydrochloride and its use as antiviral
06/20/2013WO2013087767A1 Compositions for enhancing skin antimicrobial defence
06/20/2013WO2013087749A1 Potentiation induced by pde4 inhibitors in the treatment of leukemia
06/20/2013WO2013087744A1 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
06/20/2013WO2013087739A1 4-aryl imidazole derivatives as mglur5 positive allosteric modulators
06/20/2013WO2013087738A1 Novel compounds
06/20/2013WO2013087725A1 Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
06/20/2013WO2013087647A1 Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
06/20/2013WO2013087643A1 1,3,5 -triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof
06/20/2013WO2013087591A1 Solid forms of (1r,4r)-6'-fluoro-(n,n-dimethyl)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
06/20/2013WO2013087590A1 Solid forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine hydrochloride
06/20/2013WO2013087581A1 Amino-substituted imidazopyridazines
06/20/2013WO2013087579A1 Substituted triazolopyridines and their use as ttk inhibitors
06/20/2013WO2013087578A1 Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
06/20/2013WO2013087575A1 (11ss,17ss)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoro- ethyl)estra-4,9-dien-3-one for the treatment of charcot marie tooth disease
06/20/2013WO2013087563A1 Pharmaceutical composition comprising (s)-2-(2-oxopyrrolidin-1-yl)butanamid
06/20/2013WO2013087546A1 Pharmaceutical composition with improved bioavailability for high melting hydrophobic compound
06/20/2013WO2013087544A1 Piperidinyl naphthylacetic acids
06/20/2013WO2013087410A1 Treatment of migraine headaches, in particular cluster headaches
06/20/2013WO2013087238A1 Preparation of sevelamer with reduced content of allylamine
06/20/2013WO2013087237A1 Purification of sevelamer and related polyallylamines
06/20/2013WO2013087090A1 Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
06/20/2013WO2013087083A1 Particles comprising single stranded rna and double stranded rna for immunomodulation
06/20/2013WO2013087042A1 Medical composition for preventing or treating amyloid β peptide related diseases or conditions
06/20/2013WO2013087023A1 Natural weight reduction health composition and application thereof
06/20/2013WO2013087004A1 Imidazolidinedione compounds and their uses
06/20/2013WO2013086980A1 Sulfonylurea guanidine, preparation method and use thereof
06/20/2013WO2013086804A1 4-pyridyl porphyrin bridged crisscross quad-nuclear platinum complex, and preparation method and anti-tumor activity thereof
06/20/2013WO2013086803A1 Trinuclear platinum complex having y-shaped structure and targeting property thereof for human gastric adenocarcinoma cells
06/20/2013WO2013086639A1 Mutations indicative of weaver syndrome
06/20/2013WO2013086621A1 Method for extracting anthocyanin derivatives from a plant source
06/20/2013WO2013063458A3 Inhibiting g protein coupled receptor 6 kinase polypeptides
06/20/2013WO2013062332A3 Vascular anti-aging composition including syringaresinol
06/20/2013WO2013062316A3 Composition containing modafinil or the derivatives thereof for treating vascular diseases or kca3.1-channel-mediated diseases
06/20/2013WO2013062294A3 Improved preparation method for mitiglinide calcium
06/20/2013WO2013062247A3 Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same
06/20/2013WO2013061279A4 Uses of indole-ketones or indolidones as neuro-protective drugs
06/20/2013WO2013060744A3 1, 2, 4 - oxadiazole derivatives as ethr inhibitors for use in the treatment tuberculosis
06/20/2013WO2013058681A3 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof
06/20/2013WO2013058632A3 Composition containing ohioensins f as a polytrichastrum alpinum-derived novel compound for preventing or treating arteriosclerosis
1 ... 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 ... 7860